Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications
US6133267A · kind A · utility
0Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 14, 1999 |
| Grant date | Oct 17, 2000 |
| Priority date | — |
| Expiry date | Jun 14, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof in which R.sub.1 and R.sub.2 are independently H or methyl (for example 1,1-dimethyl-2-(2-morpholinophenyl)guanidine fumarate) is used for inhibiting the formation of advanced glycosylation end-products, and for the treatment and/or prophylaxis of long-term complications associated with diabetes, such as atherosclerosis, nephropathy, neuropathy and retinopathy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.